$23.26
3.55% today
Nasdaq, Apr 04, 07:47 pm CET
ISIN
US14888U1016
Symbol
CPRX
Sector
Industry

Catalyst Pharmaceuticals, Inc. Stock News

Neutral
Investors Business Daily
about 2 hours ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Negative
The Motley Fool
about 22 hours ago
As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst trading days in years, and almost no sector of the economy was spared.
Positive
Investors Business Daily
8 days ago
This IBD 50 holding holds top notch ratings amid a market downturn. The post Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win appeared first on Investor's Business Daily.
Positive
FXEmpire
9 days ago
Big Money continues buying Catalyst Pharmaceuticals, Inc. (CPRX).
Positive
Seeking Alpha
24 days ago
Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues, undervaluing future upside potentials. CPRX stock's upside potential is driven by expanding drug distribution, increasing dosages, and acquiring additional drugs, while downside risk is limited by strong cash flow and exclusivity runways. The base case is very realistic, offerin...
Neutral
GlobeNewsWire
about one month ago
CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other me...
Positive
Seeking Alpha
about one month ago
Firdapse drives Catalyst Pharmaceuticals, Inc.'s revenue with a 37% CAGR since its 2019 launch, boosted by an FDA-approved 100 mg dose expansion. Agamree targets DMD and has so far generated $46 million in its first 10 months, which does attest to its strong growth potential. However, Fycompa still faces generic competition starting May 2025. So it remains to be seen if they'll achieve a “manag...
Positive
The Motley Fool
about one month ago
Shares of drugmaker Catalyst Pharmaceuticals (CPRX 5.54%) are up a little more than 8% as of midday on Thursday, down slightly from an intraday peak gain of nearly 13%. The company's fourth-quarter results posted after Wednesday's close were markedly better than expected.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today